This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Optum RX says US FTC insulin suit’s ‘materially different’ facts merit split hearings

( October 23, 2024, 21:31 GMT | Official Statement) -- MLex Summary: Optum Rx told a US Federal Trade Commission administrative law judge that "materially different" factual allegations merit separate proceedings in an agency suit over insulin prices brought against Optum, Caremark Rx and Express Scripts. "It is unfair for the Commission to lump Respondents’ conduct together in a Complaint that, in many respects, elides these significant differences, and expect fierce competitors to jointly defend each other’s conduct in the same action," Optum said in a motion for a separate evidentiary hearing filed in  the FTC's administrative court.See attached file....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections